Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing

By Bauss Frieder   Russell R.  

Osteoporosis International, Vol. 15, Iss. 6, 2004-06 ,pp. : 423-433

Springer Publishing Company

Access to resources Recommend Favorite

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

By Emkey Ronald  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 341-349

Future Medicine

Access to resources Recommend Favorite

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg

By Epstein S.   Jeglitsch M.   McCloskey E.  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2951-2960

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

By Earnshaw S. R.   Graham C. N.   Ettinger B.   Amonkar M. M.   Lynch N. O.   Middelhoven H.  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2517-2529

Informa Healthcare

Access to resources Recommend Favorite

Bisphosphonates for osteoporosis prevention and treatment

By Jarvis Courtney   Morin Anna   Lynch Ann  

Clinical Review in Bone and Mineral Metabolism, Vol. 3, Iss. 1, 2005-03 ,pp. : 3-18

Humana Press, Inc

Access to resources Recommend Favorite